Member Info for Saxondale

Interesting post you did the other day Oil about shares slipping over to the Nas . Tie that in with investors surely now starting to hold their shares a bit tighter , now that the trumpet of the short season is buzzing , and we are getting a smaller free float by the day .
Still interested how Hibiscus funding is going to work . The $6.1 million may get the phase 2 part covered , but surely you'd need more to run through with the phase3 . Perhaps the DoD have a clause whereby if phase2 results are positive they come onboard with further support ? I'm not really sure how these things work to be honest . You'd assume a trial wouldn't begin unless the sponsor had funding to see it through.
Also , a massive grant like this surely comes with strings attached ? They aren't doing it for the good of science . Presumably there are further agreements to be made on trial completion . Either way , its great to have them on board .
San Antonio is virtually twinned with Turku now , what with Clevegen being trialed at The University of Texas Health Science Center there .
I remember spotting the new addition to their SAB board - Prof Tyler Curiel ( also from UT Health San Antonio ) , months before we hear about the 59th Medical Wings involvement ( San Antonio).

The more that Faron embed themselves into the US Medical world , the better . And the dream US listing would almost be obligatory if Clevegen and Traumakine go the way we hope .

Useful website with info for the general public on how Activ-2 works and how to enroll

https://www.riseabovecovid.org/en/about-us

I loved the way he talked about how being backed by the US Govt massively increased your chances of having a success .
Good possibility of early EUA off interim data
3 trials
Warp Speed ahead !

Ok we're not out of the woods yet , but that is one hell of a reassuring RNS

Another great update . Who cares what the price is tomorrow unless you want to sell .
These shares will only get more valuable in the long term

Man's own defense system in the fight against cancer

Last Wednesday, Faron had some good news to tell about the cancer drug Clevegen (you switch to another service). Promising evidence has been obtained from patient studies. However, there is still a long way to go before a marketing authorization can be obtained from the first and second phase studies.

Clevegen seeks to act on cells that lower immunity and thus strengthen the body's own defense system in a cancer patient.

- Patient studies have now proven that this is exactly what is happening. The patients we have treated have no longer had any option for other treatments. They have already gone through several different treatments, but nothing has worked, says Markku Jalkanen.
According to Jalkanen, the outlook for anticancer drugs has improved significantly over the past year and a half. Patients have also tolerated drug therapy well.

The CEO believes Fon’s anticancer drug could be on the market at its fastest in a couple of years.
The trumpet of the short season is buzzing

CEO Markku Jalkanen calls himself a serious researcher. He may present his case very enthusiastically at times, but he doesn’t forget his company slogan: nothing beats good data - nothing beats good information.

No matter how excited Jalkanen is, he stays on the facts, as decisions must be based on reliable information.

That is why he is so emaciated that he has had to notice the widespread suspicion during Donald Trump's presidency. When is it about the information being researched, when is it about plain mouth?

- For me personally, it is the worst disappointment of Trump's reign. Or even more disappointing was to find that the same behavior has spread almost worldwide. As if the facts no longer had any purpose.

According to Markku Jalkanen, so many have registered as experts. He doesn’t stop to wonder where that kind of expertise has suddenly come from.

- It feels like my whole upbringing and education has been thrown in the trash at once. I do my job because I make research findings into medicines for people. These aren’t any hokkuspokkus stuff.

So does Markku Jalkanen see in his own work that the line between the researched information and the so-called bunny speech is blurred?

- That's what happened. Quite a lot.

Help for the wounded on the battlefields too?

The involvement of the US Department of Defense is also relevant to Traumakine's broader use.

According to CEO Markku Jalkanen, trauma patients can be helpful in many other trauma conditions as well.

- These can occur even after a surgeon's operation or in a traffic accident. Probably the US Department of Defense also has in mind whether wounded patients on the battlefield can be treated in this way, says Jalkanen.

In addition to the lungs, corrective treatment for organ damage can also target the kidneys, liver or even the brain.

Markku Jalkanen expects results from further research in the United States already this year.

Great little article thanks

Turku President and CEO Markku Jalkanen has had a sensitive smile since last week. The price of the pharmaceutical development company Faron Pharmaceuticals rose sharply on both the Helsinki and London stock exchanges.

Highlights include the anticancer drug Clevegen and the lung injury drug Traumakine.

On Monday last week, the company announced (you switch to another service)that the U.S. Department of Defense is making a significant contribution to patient research on Traumakine treatment developed by Faro. $ 6.1 million will significantly accelerate further research into a drug that repairs lung tissue damage.

- It is important for us that we can now test the drug in the USA with COVID 19 patients, says Markku Jalkanen, the founder of Faro.

Traumakine is believed to help with coronavirus-induced lung disease and reduce viral deaths.

Interferon beta is given to the patient intravenously. It binds to healthy cells and triggers defensive reactions in them, which prevent viruses from invading the cells.

A coronary patient may die because the lungs stop working. Traumakine is specifically designed to maintain the functioning of key organs.

- We already have an inherent system for this. For everyone, it just isn’t effective enough. Therefore, additional interferon beta is needed.

Markku Jalkanen compares the help brought by Traumakinen to a situation where a diabetic is helped by giving insulin.

Was that Fox Australia or USA or are they all the same - Interviewer sounded a bit Aussie . Either way , it shows how unused to saying the word 'TREATMENT' these presenters are . He got mixed up twice - so used to saying 'TEST or VACCINE ' . He'll have to practice in the mirror tonight .
The big one will be when a Fauci or a Biden team guy mentions Synairgen - won't be long I reckon .

As part of a working relationship established with Faron, the 59th Medical Wing of the US Air Force and the DoD will continue primate studies to evaluate Traumakine's role in preventing multiple organ dysfunction syndrome (MODS) after ischemia-reperfusion injury caused by a major trauma.

So another bit of info into what the DoD have been up to . I'm pretty sure you don't experiment with primates unless you the science is of such a high quality to justify their use . The DoD obviously have confidence so far to provide $6.1 million to accelerate the Traumakine program . For them , its the combat trauma element that they have been studying .

We sure have learn't alot more this last week .

I'm guessing patents will have be applied for Traumakine and systemic inflammatory response syndrome (SIRS) .

And I've never seen Markku so close to wanting to spill the beans .
We can't be far away now -

I think we are on a 15 min delay with whats showing there . Hopefully they'll be filling their boots

well spotted Dan , I'd missed that . Amazing what a day makes . Yesterdays tree shake looks like just that . never seen Markku more confident about the right time to be invested is right now .

If they put it on Ebay , I sure hope they include a 'BUY IT NOW ' price too . Give us a more of a clue lol .

The study sponsorship has now been changed to Faron, with Professor Daniel Talmor from Harvard University's Beth Israel Deaconess Medical Center, as the Principal Investigator.

Does this mean that its Faron that is paying for the trial ( along with the $6.1 million grant ) , so at the moment it's still 100% wholey owned .

If it was changed to Faron , what was it before ?

Nothing on the NIH Clinical Trial site regarding Hibiscus yet .
Also Markku had left the door open as to what the final partnership/funding was going to be for Hibiscus .
I assume $6.1 won't cover it ?
So more news shortly ?

Updates coming thick and fast now .
New patents
Just keeping better
Finally we get priority over steroids in a trial
Interim analysis after 70 patients
Continued build up of commercial manufacture with AGC - he did say at that presentation he was glad they chose AGC as they have the capacity.
SP should correct itself shortly

That is a really well written & concise summary of where Synairgen is today .
The scientific argument was always robust .
The doors to success are all swinging open

Either some profit taking or tree shaking going on , seems to be bouncing back whatever it was .
Its usually the 3 month slow slide in between news .
Volumes are much higher at the moment , so who knows .
Another top up opportunity ( not that I really need one - but thanks for the chance )

Joe ?

Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces a clinical trial agreement to include its inhaled interferon beta-1a treatment (SNG001) in the ACTIV-2/A5401 Phase II/III trial in patients with COVID-19 not yet requiring hospitalisation.

Does that mean this is to be trialed on people BEFORE hospitalisation , i.e at home ?

Thats the bigger market - and one of SNGs USPs